Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis

Abstract Objective: This study sought to determine the impact of the World Health Organization's directly observed treatment strategy (DOTS) compared with that of DOTS-plus on tuberculosis deaths, mainly in the developing world. Design: Decision analysis with Monte Carlo simulation of a Markov decision tree. Data sources: People with smear positive pulmonary tuberculosis. Data analysis: Analyses modelled different levels of programme effectiveness of DOTS and DOTS-plus, and high (10%) and intermediate (3%) proportions of primary multidrug resistant tuberculosis, while accounting for exogenous reinfection. Main outcome measure: The cumulative number of tuberculosis deaths per 100 000 population over 10 years. Results: The model predicted that under DOTS, 276 people would die from tuberculosis (24 multidrug resistant and 252 not multidrug resistant) over 10 years under optimal implementation in an area with 3% primary multidrug resistant tuberculosis. Optimal implementation of DOTS-plus would result in four (1.5%) fewer deaths. If implementation of DOTS-plus were to result in a decrease of just 5% in the effectiveness of DOTS, 16% more people would die with tuberculosis than under DOTS alone. In an area with 10% primary multidrug resistant tuberculosis, 10% fewer deaths would occur under optimal DOTS-plus than under optimal DOTS, but 16% more deaths would occur if implementation of DOTS-plus were to result in a 5% decrease in the effectiveness of DOTS Conclusions: Under optimal implementation, fewer tuberculosis deaths would occur under DOTS-plus than under DOTS. If, however, implementation of DOTS-plus were associated with even minimal decreases in the effectiveness of treatment, substantially more patients would die than under DOTS. What is already known on this topic DOTS is an effective, albeit underused, strategy for treating tuberculosis DOTS may be insufficiently effective in treating multidrug resistant tuberculosis The use of toxic reserve drugs (DOTS-plus) is an effective but costly strategy for treating multidrug resistant tuberculosis The impact of the implementation of DOTS-plus on overall tuberculosis control is unknown What this study adds If implementation of DOTS-plus is associated with even minimal decreases in the effectiveness of DOTS, more patients would die with tuberculosis under DOTS-plus than under DOTS alone If DOTS-plus is implemented, it must not divert resources from and decrease the effectiveness of DOTS

[1]  C. Dye,et al.  Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru , 2002, The Lancet.

[2]  Brian G. Williams,et al.  Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.

[3]  W. Lew,et al.  Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  Rajesh K. Gupta,et al.  Responding to Market Failures in Tuberculosis Control , 2001, Science.

[5]  L. Karasulu,et al.  The treatment of multidrug-resistant tuberculosis in Turkey. , 2001, The New England journal of medicine.

[6]  Christopher Dye,et al.  Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.

[7]  Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[8]  A. Aerts,et al.  DOTS and DOTS plus: what's in a name. , 2001, The International Journal of Tuberculosis and Lung Disease.

[9]  P. Farmer,et al.  Public health. Responding to market failures in tuberculosis control. , 2001, Science.

[10]  Reichman Lb,et al.  DOTS and DOTS plus: what's in a name. , 2000 .

[11]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[12]  T. Frieden,et al.  The status and prospects of tuberculosis control in India. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  Christopher Dye,et al.  Global burden of tuberculosis , 1999 .

[14]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[15]  C. Dye,et al.  Rational 'DOTS plus' for the control of MDR-TB. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  Jim Y. Kim,et al.  Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus” , 1998, BMJ.

[17]  H L Rieder,et al.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 1998, The New England journal of medicine.

[18]  G. Peersman,et al.  A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. , 1998 .

[19]  S. Weis,et al.  A survey of drug‐resistant Mycobacterium tuberculosis and its relationship to HIV infection , 1998, AIDS.

[20]  Global Tuberculosis Programme Global tuberculosis control : WHO report , 1997 .

[21]  S. A. Abdool Karim,et al.  Multidrug-resistant tuberculosis in patients without HIV infection. , 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[22]  F. Portaels,et al.  Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. , 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  Salim Yusuf,et al.  Risk factors for acute myocardial infarction in Indians: a case-control study , 1996, The Lancet.

[24]  Christopher J. L. Murray Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis , 1996, The Lancet.

[25]  T. Frieden,et al.  Emergence of fluoroquinolone-resistant tuberculosis in New York City , 1995, The Lancet.

[26]  L. Ackerson,et al.  Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.

[27]  D. Mitchison,et al.  Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[28]  S. Pauker,et al.  The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.

[29]  K. Stýblo,et al.  Recent advances in epidemiological research in tuberculosis. , 1982, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.

[30]  B. Thompson Survival Rates in Pulmonary Tuberculosis , 1943, British medical journal.

[31]  G. J. Drolet,et al.  Present Trend of Case Fatality Rates in Tuberculosis. , 1938 .